Real-Life Cefiderocol Use in Bone and Joint Infection: A French National Cohort

Real-Life Cefiderocol Use in Bone and Joint Infection: A French National Cohort

<b>Background</b>: Cefiderocol (CFD) is a novel siderophore cephalosporin developed for the treatment of infections involving multidrug-resistant (MDR) Gram-negative bacilli (GNB) infections (1–3). For bone and joint infections (BJIs), the use of CFD is currently neither part of its mark...

Full description

Saved in:
Bibliographic Details
Main Authors: Ava Diarra, Maxime Degrendel, Isabelle Eberl, Tristan Ferry, Karim Jaffal, Lelia Escaut, Antoine Asquier Khati, Nicolas Taar, Johan Courjon, Laurène Deconinck, Benjamin Lefevre, Aurélie Baldolli, Messaline Bermejo, Alexandre Bleibtreu, Vincent Dacquet, Victoire de Lastours, Pierre Gazeau, Romaric Larcher, Pierre Patoz, Olivier Robineau, Nicolas Rouzic, Naomi Sayre, Diana Isabela Costescu Strachinaru, Benjamin Valentin, Heidi Wille, Eric Senneville
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Antibiotics
Subjects:
cefiderocol
bone and joint infection
Gram-negative bacilli
tolerance
outcome
Online Access:https://www.mdpi.com/2079-6382/14/4/388
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2079-6382/14/4/388

Similar Items